glp-1 drug news A wave of new #GLP1 options for type 2 #Diabetes and #Obesity was a major focus at #ADA2026. In the latest JAMA Medical podcast, Jennifer Abbasi interviews Rita Kalyani, MD GLP-1 Drugs from the Gray

Here, we present the NTD complexes with Ent1, Ent2, Ent5.1 (LIDL peptide), Apl2.1 (LLDLF peptide) and Yap1801 (Fig.2 and Supplementary Fig 1.)

Asthma Allergy 14, 15111525

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled parallel-group study

Regen Med 7 (3), 369385

& Pfeifer, H

The peptides excellent tolerability, minimal side effect burden, and absence of concerning metabolic effects distinguish it within the peptide landscape and may make it suitable for individuals seeking approaches with favorable safety characteristics